Patents by Inventor Yuejin Liu

Yuejin Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240142176
    Abstract: The present invention discloses a heat exchanger and a heat exchange method, which can recover heat from a high-temperature fluid during transport. The heat exchanger includes a closed heat exchange region and a heat-receiving fluid coil mounted therein. The heat exchange method is to pass the high-temperature fluid through a heat exchange base plate in contact therewith so as to transfer heat to the heat-receiving fluid. According to the design of the heat exchanger in the present invention, modification of the original transport pipeline and mounting of a new apparatus are very convenient, the heat exchange area can be increased while saving the cost, and the heat exchange efficiency is improved.
    Type: Application
    Filed: October 25, 2023
    Publication date: May 2, 2024
    Inventors: Ruochen LIU, Yuquan GU, Peter VAN KAMPEN, Yuejin PAN
  • Patent number: 11813306
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Grant
    Filed: March 12, 2021
    Date of Patent: November 14, 2023
    Assignee: Novartis AG
    Inventors: Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Liansheng Su, Lihua Yang, Rui Zheng
  • Publication number: 20230089867
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein X1, R1, R2, R3, R4, R5, R6, R6?, R7, R7?, R8, R9, R9?, R10, R11, R12, and n are described herein.
    Type: Application
    Filed: November 26, 2019
    Publication date: March 23, 2023
    Inventors: Christopher BECKER, Brian Addison DECHRISTOPHER, Alec Nathanson FLYER, Adam FRIEDMAN, Christian GAMPE, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Tyler HARRISON, Qian LIU, Eugene Yuejin LIU, I, Justin Yik Ching MAO, Lauren Gilchrist MONOVICH, Tajesh Jayprakash PATEL, Carina Cristina SANCHEZ, Liansheng SU, Lihua YANG, Rui ZHENG
  • Publication number: 20220024981
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, or tautomer thereof, wherein R1, X1, X2, X3, X4, X5, X6, X7, X8, X9, X10, X11, X12, and X13 are described herein.
    Type: Application
    Filed: November 26, 2019
    Publication date: January 27, 2022
    Inventors: Alec Nathanson FLYER, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Ian LEWIS, Eugene Yuejin LIU, Andreas MARZINZIK, Lauren Gilchrist MONOVICH, Johannes OTTL, Tajesh Jayprakash PATEL, Patrick Crawford REID, Mohindra SEEPERSAUD
  • Publication number: 20210252103
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Application
    Filed: March 12, 2021
    Publication date: August 19, 2021
    Inventors: Karin BRINER, Brian Addison DECHRISTOPHER, Alec Nathanson FLYER, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Eugene Yuejin LIU, Justin Yik Ching MAO, Lauren Gilchrist MONOVICH, Tajesh Jayprakash PATEL, Liansheng SU, Lihua YANG, Rui ZHENG
  • Patent number: 11026993
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: June 8, 2021
    Assignee: Novartis AG
    Inventors: Karin Briner, Brian Addison Dechristopher, Alec Nathanson Flyer, Andrei Alexandrovich Golosov, Philipp Grosche, Eugene Yuejin Liu, Justin Yik Ching Mao, Lauren Gilchrist Monovich, Tajesh Jayprakash Patel, Carina Cristina Sanchez, Liansheng Su, Lihua Yang, Rui Zheng
  • Patent number: 10884880
    Abstract: A method for transmitting a request message and an apparatus are disclosed, to resolve a prior-art problem that in an ICT network, when a request message is transmitted, a probability that the request message fails to be transmitted is increased, and reliability of transmitting the request message is reduced. The method includes: determining, by a dispatcher according to information that is about a first controller and that is included in a received request message, a corresponding first driver adaptation plug-in group, where the first controller is connected to at least one driver adaptation plug-in included in the first driver adaptation plug-in group; and selecting, by the dispatcher from the at least one driver adaptation plug-in, at least one to-be-selected driver adaptation plug-in whose running status is normal, and eventually sending the request message to the first controller by using one to-be-selected driver adaptation plug-in.
    Type: Grant
    Filed: August 13, 2018
    Date of Patent: January 5, 2021
    Assignee: HUAWEI TECHNOLOGIES CO., LTD.
    Inventors: Yuejin Liu, Youyu Jiang
  • Publication number: 20200164024
    Abstract: The disclosure relates to inhibitors of PCSK9 useful in the treatment of cholesterol lipid metabolism, and other diseases in which PCSK9 plays a role, having the Formula (I): or a pharmaceutically acceptable salt, hydrate, solvate, prodrug, stereoisomer, N-oxide, or tautomer thereof, wherein R1, R1, R1, R1, R1, R1, R1, R1, R1, X1, X2, and X3 are described herein.
    Type: Application
    Filed: November 26, 2019
    Publication date: May 28, 2020
    Inventors: Karin BRINER, Brian Addison DECHRISTOPHER, Alec Nathanson FLYER, Andrei Alexandrovich GOLOSOV, Philipp GROSCHE, Eugene Yuejin LIU, Justin Yik Ching MAO, Lauren Gilchrist MONOVICH, Tajesh Jayprakash PATEL, Carina Cristina SANCHEZ, Liansheng SU, Lihua YANG, Rui ZHENG
  • Publication number: 20180349236
    Abstract: A method for transmitting a request message and an apparatus are disclosed, to resolve a prior-art problem that in an ICT network, when a request message is transmitted, a probability that the request message fails to be transmitted is increased, and reliability of transmitting the request message is reduced. The method includes: determining, by a dispatcher according to information that is about a first controller and that is included in a received request message, a corresponding first driver adaptation plug-in group, where the first controller is connected to at least one driver adaptation plug-in included in the first driver adaptation plug-in group; and selecting, by the dispatcher from the at least one driver adaptation plug-in, at least one to-be-selected driver adaptation plug-in whose running status is normal, and eventually sending the request message to the first controller by using one to-be-selected driver adaptation plug-in.
    Type: Application
    Filed: August 13, 2018
    Publication date: December 6, 2018
    Inventors: Yuejin Liu, Youyu Jiang